Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study.
Clin Cardiol. 2011 Apr; 34(4):211-7.CC

Abstract

BACKGROUND

Studies have suggested that micronutrient deficiency has some role in the progression of chronic heart failure (CHF).

HYPOTHESIS

Oral supplementation with coenzyme Q(10) (CoQ(10)) and creatine may reduce mitochondrial dysfunction that contributes to impaired physical performance in CHF.

METHODS

We conducted a randomized, double-blind, placebo-controlled trial to determine the effect of a mixture of water-soluble CoQ(10) (CoQ(10) terclatrate; Q-ter) and creatine on exercise tolerance and health-related quality of life. Exercise tolerance was measured as total work capacity (kg·m) and peak oxygen consumption (VO(2), mL/min/kg), both from a cardiopulmonary exercise test. Health-related quality of life was measured by the Sickness Impact Profile (SIP) in CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 35%). After baseline assessment, 67 patients with stable CHF were randomized to receive Q-ter 320 mg + creatine 340 mg (n = 35) or placebo (n = 32) once daily for 8 weeks.

RESULTS

At multivariate analysis, 8-week peak VO(2) was significantly higher in the active treatment group than in the placebo group (+1.8 ± 0.9 mL/min/kg, 95% CI: 0.1-3.6, P < 0.05). No untoward effects occurred in either group.

CONCLUSIONS

This study suggests that oral Q-ter and creatine, added to conventional drug therapy, exert some beneficial effect on physical performance in stable systolic CHF. Results may support the design of larger studies aimed at assessing the long-term effects of this treatment on functional status and harder outcomes.

Authors+Show Affiliations

Department of Critical Care Medicine and Surgery, Unit of Gerontology and Geriatrics, University of Florence and Azienda Ospedaliero-Universitaria Careggi, Florence, Italy. fumadue@tin.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21462215

Citation

Fumagalli, Stefano, et al. "Coenzyme Q10 Terclatrate and Creatine in Chronic Heart Failure: a Randomized, Placebo-controlled, Double-blind Study." Clinical Cardiology, vol. 34, no. 4, 2011, pp. 211-7.
Fumagalli S, Fattirolli F, Guarducci L, et al. Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clin Cardiol. 2011;34(4):211-7.
Fumagalli, S., Fattirolli, F., Guarducci, L., Cellai, T., Baldasseroni, S., Tarantini, F., Di Bari, M., Masotti, G., & Marchionni, N. (2011). Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. Clinical Cardiology, 34(4), 211-7. https://doi.org/10.1002/clc.20846
Fumagalli S, et al. Coenzyme Q10 Terclatrate and Creatine in Chronic Heart Failure: a Randomized, Placebo-controlled, Double-blind Study. Clin Cardiol. 2011;34(4):211-7. PubMed PMID: 21462215.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 terclatrate and creatine in chronic heart failure: a randomized, placebo-controlled, double-blind study. AU - Fumagalli,Stefano, AU - Fattirolli,Francesco, AU - Guarducci,Lorenzo, AU - Cellai,Tommaso, AU - Baldasseroni,Samuele, AU - Tarantini,Francesca, AU - Di Bari,Mauro, AU - Masotti,Giulio, AU - Marchionni,Niccolò, PY - 2011/4/5/entrez PY - 2011/4/5/pubmed PY - 2011/7/26/medline SP - 211 EP - 7 JF - Clinical cardiology JO - Clin Cardiol VL - 34 IS - 4 N2 - BACKGROUND: Studies have suggested that micronutrient deficiency has some role in the progression of chronic heart failure (CHF). HYPOTHESIS: Oral supplementation with coenzyme Q(10) (CoQ(10)) and creatine may reduce mitochondrial dysfunction that contributes to impaired physical performance in CHF. METHODS: We conducted a randomized, double-blind, placebo-controlled trial to determine the effect of a mixture of water-soluble CoQ(10) (CoQ(10) terclatrate; Q-ter) and creatine on exercise tolerance and health-related quality of life. Exercise tolerance was measured as total work capacity (kg·m) and peak oxygen consumption (VO(2), mL/min/kg), both from a cardiopulmonary exercise test. Health-related quality of life was measured by the Sickness Impact Profile (SIP) in CHF secondary to left ventricular systolic dysfunction (left ventricular ejection fraction ≤ 35%). After baseline assessment, 67 patients with stable CHF were randomized to receive Q-ter 320 mg + creatine 340 mg (n = 35) or placebo (n = 32) once daily for 8 weeks. RESULTS: At multivariate analysis, 8-week peak VO(2) was significantly higher in the active treatment group than in the placebo group (+1.8 ± 0.9 mL/min/kg, 95% CI: 0.1-3.6, P < 0.05). No untoward effects occurred in either group. CONCLUSIONS: This study suggests that oral Q-ter and creatine, added to conventional drug therapy, exert some beneficial effect on physical performance in stable systolic CHF. Results may support the design of larger studies aimed at assessing the long-term effects of this treatment on functional status and harder outcomes. SN - 1932-8737 UR - https://www.unboundmedicine.com/medline/citation/21462215/Coenzyme_Q10_terclatrate_and_creatine_in_chronic_heart_failure:_a_randomized_placebo_controlled_double_blind_study_ L2 - https://doi.org/10.1002/clc.20846 DB - PRIME DP - Unbound Medicine ER -